Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ: EDIT )

1.460 +0.090 (+6.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027. 
Via Stocktwits
Earnings Scheduled For March 5, 2025
Via Benzinga
Peering Into Editas Medicine's Recent Short Interest
Via Benzinga
12 Analysts Have This To Say About Editas Medicine
Via Benzinga
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts
Via Benzinga
What's going on in today's session
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Top movers in Thursday's session
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Where Editas Medicine Stands With Analysts
Via Benzinga
Unveiling 5 Analyst Insights On Editas Medicine
Via Benzinga
The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
Via Benzinga
Top movers analysis one hour before the close of the markets on 2025-02-19: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements. 
Via Chartmill
Here are the top movers in Wednesday's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution
Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines. 
Via Benzinga
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026
Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing. 
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
Via Talk Markets
Topics Stocks / Equities
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13. 
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
Looking for Stock Bargains With Room to Run? Try This.
Investing tips from Bill Mann, The Motley Fool's director of small-cap research. 
Via The Motley Fool
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. 
Via InvestorPlace
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. 
Via InvestorPlace
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks. 
Via InvestorPlace
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions. 
Via InvestorPlace
Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential
Invest in these undervalued stocks poised for long-term growth as Wall Street shifts focus to broader market gains. 
Via InvestorPlace
1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
The company has great potential if and when it enters the commercial stage. 
Via The Motley Fool
EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024
EDIT stock results show that Editas Medicine missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.